Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to evaluate the efficacy and safety of Donafenib combined with PD-1 antibody in neoadjuvant therapy of locally advanced thyroid cancer.
Thyroid Cancer
DRUG: Donafeib with Sintilimab
Objective response rate, The proportion of patients with complete response (CR) and partial response (PR) to the total number of evaluable cases., From enrollment to the end of treatment at 4 weeks
R0/R1 resection rate, The rate of patients who receive R0 or R1 resection surgery after neoadjuvant treatment in all patients undergo surgery., From enrollment to the end of treatment at 4 weeks|Progression free survival, The time from surgery to tumor progression, including local-regional recurrence and distant metastasis, 5 years after surgery|Tumor recurrence time, Time from treatment to the first date received CR or PR status, 5 years after surgery|disease control rate, The percentage of patients who received CR„ÄÅPR or SD status of all patients enrolled, 5 years after surgery|3-year local recurrence-free survival, 3-year local recurrence-free survival, From enrollment to the end of treatment at 3 years|5-year local recurrence-free survival, 5-year local recurrence-free survival, From enrollment to the end of treatment at 5 years
This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to evaluate the efficacy and safety of Donafenib combined with PD-1 antibody in neoadjuvant therapy of locally advanced thyroid cancer.